Physician profile
Benjamin Cohen
NPI 1053301085
$10,680.44
in general payments reported to CMS, 2019-2025
38 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $1,274 · 2021: $1,479 · 2022: $1,345 · 2023: $1,758 · 2024: $1,662 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,386 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,385.61 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,563.45 | 2019-2025 | Ilumya |
| Abbvie INC. | $957.60 | 2019-2025 | Skyrizi, Rinvoq |
| Journey Medical Corporation | $900.84 | 2019-2025 | |
| Leo Pharma INC. | $898.47 | 2019-2025 | Adbry |
| Incyte Corporation | $789.03 | 2022-2025 | Opzelura |
| Almirall LLC | $688.15 | 2020-2025 | Seysara |
| Galderma Laboratories, L.P. | $623.44 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Genzyme Corporation | $344.54 | 2020-2025 | |
| Epi Health, LLC | $325.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $319.03 | 2019-2025 | |
| Janssen Biotech, INC. | $313.83 | 2021-2024 | Tremfya, Simponi Aria, Stelara |
| Vyne Pharmaceuticals INC. | $301.27 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $291.81 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $288.96 | 2023-2024 | Vtama |
| Merz North America, INC. | $261.21 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $234.88 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $228.18 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $210.52 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $185.64 | 2019-2025 | Cabtreo, Siliq |
| Lilly USA, LLC | $147.10 | 2022-2023 | Taltz, Olumiant |
| Amgen INC. | $139.55 | 2023-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $96.54 | 2019-2025 | Libtayo |
| Verrica Pharmaceuticals INC. | $92.98 | 2023-2024 | Ycanth |
| Organon LLC | $67.36 | 2025 | Vtama |
| Pfizer INC. | $66.97 | 2022-2025 | |
| Sensus Healthcare, INC. | $55.89 | 2024 | |
| Insulet Corporation | $51.26 | 2025 | Omnipod |
| Encore Dermatology INC. | $43.45 | 2019 | |
| Promius Pharma LLC | $29.73 | 2019 | |
| Hydrofera LLC | $21.95 | 2022 | |
| Dusa Pharmaceuticals, INC. | $20.59 | 2019 | |
| Biofrontera INC. | $20.05 | 2019 | |
| Glenmark Therapeutics INC. | $19.00 | 2019 | |
| Botanix Sb INC | $17.96 | 2025 | Sofdra |
| Lnhc, INC | $17.77 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $16.62 | 2025 | Vyjuvek |
| Aclaris Therapeutics, INC. | $15.21 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.